Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced Sunday that the U.S. Food and Drug Administration has approved the ...

Eisai (ESAIY) and Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has approved the Supplemental Biologics License ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Shares of Biogen Inc. (NASDAQ:BIIB – Get Free Report) have earned a consensus rating of “Hold” from the twenty-eight ratings firms that are covering the company, MarketBeat.com reports. Sixteen ...

Stock analysts at Wedbush lowered their Q4 2024 earnings estimates for Biogen in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biotechnology ...

Per the terms of the deal, AbbVie will use Neomorph's proprietary platform to develop novel drugs targeting oncology and ...

BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

The US Food and Drug Administration (FDA) has accepted Biogen’s supplemental New Drug Application (sNDA) and the European ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a $20.8 billion biotechnology company with a robust 75.6% gross profit margin, ...

Check the time stamp on this data. Updated AI-Generated Signals for Biogen Inc. (BIIB) available here: BIIB. Type a few ...